drugset / Trial / NCT03391804
Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the efficacy and safety of ALLN-177 in reducing plasma and urinary oxalate levels in adult and pediatric patients with enteric hyperoxaluria and hyperoxalemia or primary hyperoxaluria
Timeline
- Start
- 2018-07-17
- Primary completion
- 2019-12-13
- Completion
- 2019-12-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Reloxaliase | Protein / enzyme biologic | 7500 iu | Oral |